ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GTBP GT Biopharma Inc

4.43
0.06 (1.37%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 10,831
Bid Price 4.06
Ask Price 4.81
News -
Day High 4.81

Low
3.52

52 Week Range

High
18.00

Day Low 4.36
Company Name Stock Ticker Symbol Market Type
GT Biopharma Inc GTBP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.06 1.37% 4.43 20:00:00
Open Price Low Price High Price Close Price Prev Close
4.36 4.36 4.81 4.43 4.37
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
159 10,831 $ 4.68 $ 50,645 - 3.52 - 18.00
Last Trade Time Type Quantity Stock Price Currency
17:54:13 3 $ 4.44 USD

GT Biopharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
6.12M 1.38M - 0 -20.88M -15.13 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

GT Biopharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No GTBP Message Board. Create One! See More Posts on GTBP Message Board See More Message Board Posts

Historical GTBP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.165.213.814.5234,8710.276.49%
1 Month4.355.213.814.6518,0340.081.84%
3 Months7.807.8033.526.2372,114-3.37-43.21%
6 Months7.3689.903.526.9898,432-2.94-39.88%
1 Year18.0018.003.528.91241,671-13.57-75.39%
3 Years210.00591.9933.52152.29235,777-205.57-97.89%
5 Years165.00591.9933.52154.46251,241-160.57-97.32%

GT Biopharma Description

GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Your Recent History

Delayed Upgrade Clock